ID 517 - Kwas dokozaheksaenowy, Kwas eikozapentaenowy

PL: Kwas dokozaheksaenowy, Kwas eikozapentaenowy
EN: DHA+EPA - long chain omega 3 fatty acids
Pdf: eicosapentaenoic acid

Oświadczenie (4)

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituents which are the subject of the health claims are mixed long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFA), namely docosahexaenoic acid (DHA) in combination with eicosapentaenoic acid (EPA) and, for ID 511, with docosapentaenoic acid (DPA).
The n-3 LCPUFA EPA, DHA and DPA are recognised nutrients and are measureable in foods by established methods. They are well absorbed when consumed in the form of triglycerides. This evaluation applies to EPA, DHA and, for ID 511, DPA from all sources with appropriate bioavailability in the specified amounts.
The Panel considers that the food constituents, EPA, DHA and DPA, which are the subject of the health claims are sufficiently characterised.

2.3. Utrzymanie prawidłowego stężenia trójglicerydów we krwi na czczo (ID 517)

The claimed effect is “healthy triglyceride levels”. The target population is the general population.
In the context of the proposed wordings, the Panel assumes that the claimed effect relates to the maintenance of normal (fasting) blood concentrations of triglycerides.
Triglycerides in plasma are either derived from dietary fats or synthesised in the body from other energy sources like carbohydrates. In fasting conditions, serum triglycerides are mainly transported in very-low-density lipoproteins (VLDL) synthesised in the liver. Excess calorie intake with a meal is converted to triglyceride and transported to the adipose tissue for storage. Hormones regulate the release of triglycerides from adipose tissue in order to meet energy needs between meals.
The Panel considers that maintenance of normal (fasting) blood concentrations of triglycerides is beneficial to human health.

3.3. Utrzymanie prawidłowego stężenia trójglicerydów we krwi na czczo (ID 517)

High doses (2-4 g/d) of EPA plus DHA decrease serum triglycerides in both normo- and hyperlipidaemic individuals. The effect is related both to the dose of EPA plus DHA and to the baseline concentrations of triglycerides (Jacobson, 2008). Harris (1997) observed a mean reduction of 35% in subjects with hypertriglyceridaemia and of 24% in those with serum triglycerides < 2 mmol/L. In the meta-analysis by Balk et al. (2006), a mean reduction of 27% in serum triglyceride concentrations was observed. EPA and DHA seem to have similar effects on serum triglycerides (Grimsgaard et al., 1997). The mechanisms that explain the effect include inhibition of triglyceride synthesis, stimulation of fatty acid beta-oxidation, and increased lipoprotein lipase-mediated clearance of VLDL triglycerides (Jacobsen, 2008).
In the diet and lifestyle recommendations by the American Heart Association (AHA), 2-4 g EPA plus DHA per day provided in capsules under physician‟s supervision are recommended for individuals with hypertriglyceridaemia (Lichtenstein et al., 2006).
The Panel considers that a cause and effect relationship has been established between the consumption of EPA and DHA and the reduction of (fasting) blood concentrations of triglycerides.

4.2. Utrzymanie prawidłowego stężenia trójglicerydów we krwi na czczo (ID 517)

The Panel considers that the following wording reflects the scientific evidence: “DHA and EPA contribute to the maintenance of normal triglyceride concentrations”.

5.2. Utrzymanie prawidłowego stężenia trójglicerydów we krwi na czczo (ID 517)

The Panel considers that intakes of EPA and DHA of about 2-4 g/d are required to obtain the claimed effect. The target population is adult men and women.

Warunki i możliwe ograniczenia stosowania oświadczenia

The effective dose required to maintain healthy triglyceride levels is estimated to be 500 mg n-3 LC-PUFAs per day. To carry the claim, a product should contain =30 mg n-3 LC-PUFAs per 100 g or 100 kcal, in accordance with the Update of the ANNEX of the Regulation 1924